Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma
This is a multi-center, randomized, controlled, open-label, phase IIa clinical study.The study will observe the efficacy and safety of Deuteporfin photodynamic therapy in addition to stenting compared to stenting alone in patients with unresectable advanced Perihilar Cholangiocarcinoma.
Hilar Cholangiocarcinoma
COMBINATION_PRODUCT: PDT-Deuteporfin（6 hour)|COMBINATION_PRODUCT: PDT-Deuteporfin（9 hour)|DEVICE: stenting
Overallsurvival, From the date of randomization until the date of death or the last date the subject was known to be alive, Up to 12 months
1-year survival rate, From the date of randomization until the date of death or the last date the subject was known to be alive, Up to 12 months|The change rate of Bile duct stricture, The date at the phase of baseline，at the end of first month, third month and sixth month, Up to 6 months|The change rate of serum bilirubin, The date at the phase of baseline，at the first week ，at the end of first month, Up to 1 month|The change rate of carbohydrate antigen 199(CA199), The date at the phase of baseline，at the end of first month, third month and sixth month, Up to 6 months|The change rate of Karnofsky Performance Scale(KPS), From the date of randomization until the date of death or the last date the subject was known to be alive, Up to 12 months|The change rate of European Organization for Research and Treatment of Cancer Quality Of Life Questionnaire C30 (EORTC QLQ-C30), From the date of randomization until the date of death or the last date the subject was known to be alive, Up to 12 months
This is a multi-center, randomized, controlled, open-label, phase IIa clinical study.The study will observe the efficacy and safety of Deuteporfin photodynamic therapy in addition to stenting compared to stenting alone in patients with unresectable advanced Perihilar Cholangiocarcinoma.